FUNDAMENTALS · Fundamentals · US Healthcare

Elutia (ELUT) Fundamentals 2026 — P/E 0.7x, Revenue Analysis | SniperIQ

Elutia (ELUT) is a US-listed Healthcare company in Biotechnology with a market capitalization of $41M, trading at $0.93 on the NASDAQ. This SniperIQ fundamentals page covers Elutia's valuation (P/E 0.7x, P/B 1.8x), profitability (net margin 312.1%), revenue (

2M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$41M
P/E (TTM)0.7x
Net Margin312.1%
Revenue (FY25)
2M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Elutia's market cap?

Elutia (ELUT) has a market capitalization of approximately $41M, trading at $0.93 on the NASDAQ. Market cap moves with the live share price.

What is Elutia's P/E ratio?

Elutia's trailing twelve-month P/E ratio is 0.7x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Elutia?

Elutia runs a net profit margin of 312.1%, a gross margin of 54.0%, and an operating margin of -159.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Elutia generate?

Elutia reported revenue of

2M for fiscal year 2025, with net income of $53M and earnings per share (EPS) of 1.29. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Elutia pay a dividend?

Elutia does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Elutia financially healthy?

Elutia carries a debt-to-equity ratio of 0.19x and a current ratio of 2.05x, with a market beta of 0.85. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Elutia a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Elutia (ELUT) the key facts are: market cap $41M, P/E 0.7x, revenue

2M, 52-week range 0.5-2.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Elutia's full fundamentals live

Get Elutia's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.